CRISPR/Cas分子诊断技术在结核分枝杆菌耐药性检测中的研究进展  

Research progress on CRISPR/Cas molecular diagnosis of drug-resistant Mycobacterium tuberculosis

作　　者：王苑柠 杜宗敏 Wang Yuanning;Du Zongmin(School of Public Health,Mudanjiang Medical University,Mudanjiang 157011,China;State Key Laboratory of Pathogen and Biosecurity,Academy of Military Medical Sciences,Beijing 100071,China)

机构地区：[1]牡丹江医科大学公共卫生学院,牡丹江157011 [2]中国人民解放军军事科学院军事医学研究院,病原微生物生物安全全国重点实验室,北京100071

出　　处：《中国防痨杂志》2025年第5期666-672,共7页Chinese Journal of Antituberculosis

摘　　要：结核病是全球公共卫生面临的一项严峻挑战。我国是结核病高负担国家,也是耐多药和利福平耐药结核病高负担国家。发展快速、灵敏的结核分枝杆菌耐药性检测方法对结核病的控制和治疗具有重要意义。成簇的规律间隔短回文重复序列(clustered regularly interspaced short palindromic repeats,CRISPR)作为细菌适应性免疫的组成部分,能够高效、特异性地识别和切割外源核酸靶标;同时某些CRISPR相关蛋白(Cas)具有反式切割活性,这为建立CRISPR/Cas结核病耐药性诊断技术开辟了新的研究领域。本文对CRISPR/Cas技术检测结核分枝杆菌及其耐药性的最新研究动态进行综述,并探讨该领域的未来发展趋势。Tuberculosis(TB)remains a significant global public health challenge.China is a high-burden country of TB and also a country with high burden of multidrug-resistant and rifampin-resistant TB.The development of rapid and sensitive methods for detecting the drug resistance of Mycobacterium tuberculosis is of great significance for the control and treatment of TB.Clustered regularly interspaced short palindromic repeats(CRISPR)as a component bacterial adaptive immunity can efficiently and specifically recognize and cleave exogenous nucleic acid targets.Meanwhile,some CRISPR-associated proteins(Cas)have trans-cleavage activity,paving the way for novel applications in CRISPR/Cas-based diagnostics for TB drug resistance.Therefore,this review summarizes the latest advancements in CRISPR/Cas technologies for detection Mycobacterium tuberculosis and its drug resistance,and discusses the future trends in this field.

关 键 词：分枝杆菌 结核 结核 抗多种药物性 诊断技术 分子生物学检测 综述 

分 类 号：R52[医药卫生—内科学]